Slow Capital Inc. Decreases Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Slow Capital Inc. reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,573 shares of the medical research company’s stock after selling 171 shares during the period. Slow Capital Inc.’s holdings in Amgen were worth $4,197,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. lifted its position in Amgen by 0.3% in the third quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock valued at $13,178,910,000 after acquiring an additional 165,636 shares during the last quarter. Morgan Stanley lifted its position in Amgen by 12.9% in the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after acquiring an additional 1,523,665 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Amgen by 1.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock valued at $2,132,778,000 after acquiring an additional 94,565 shares during the last quarter. Moneta Group Investment Advisors LLC lifted its position in Amgen by 83,875.6% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock valued at $1,980,571,000 after acquiring an additional 7,532,031 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Amgen by 3.8% in the third quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock valued at $1,875,306,000 after acquiring an additional 255,463 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of research reports. Oppenheimer reissued an “outperform” rating and issued a $350.00 price target on shares of Amgen in a research report on Thursday, February 1st. UBS Group reduced their price target on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a research report on Monday, January 29th. BMO Capital Markets upgraded shares of Amgen from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $286.00 to $326.00 in a research note on Tuesday, December 19th. StockNews.com lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. Finally, Truist Financial restated a “buy” rating and issued a $320.00 price objective on shares of Amgen in a research note on Friday, April 12th. Ten equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $295.30.

Amgen Stock Performance

Shares of Amgen stock traded down $0.82 on Wednesday, reaching $264.82. 987,381 shares of the stock were exchanged, compared to its average volume of 2,845,772. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The business has a fifty day moving average price of $278.62 and a two-hundred day moving average price of $281.49. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The firm has a market capitalization of $141.92 billion, a PE ratio of 21.27, a PEG ratio of 2.47 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same period last year, the company posted $4.09 earnings per share. As a group, research analysts anticipate that Amgen Inc. will post 19.47 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.40%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is currently 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.